Small Cell Lung Cancer Clinical Trials

A listing of 22 Small Cell Lung Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Small Cell Lung Cancer

1 - 12 of 22

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 22 active clinical trials seeking participants for Small Cell Lung Cancer research studies. The states with the highest number of trials for Small Cell Lung Cancer participants are Texas, California, Florida and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Irritability Associated with Autism (Children and Adolescents) Study

Recruiting

Join a clinical trial today and take a step toward finding a better solution for you. Earn money for your time and no-cost medical treatment is provided.

Learn More

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

NCT02146170

Recruiting

Background: - Lung cancer is the leading cause of cancer-related death worldwide. It causes more than one million deaths every year. Researchers want to gather tissue samples from people with lung and thymic cancers to understand the disease better. This may lead to new ways to diagnose and treat it. Objective: - To collect tissue samples for use in the study of lung cancers. Eligibility: - Adults over age 18 with non-small cell lung cancer, small cell lung cancer, extra pulmonary small cel... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

05/15/2024

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, Thymic Epithelial Tumors

Learn More ›

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

NCT03554473

Recruiting

BACKGROUND: Small cell lung cancer (SCLC) is an aggressive cancer with a poor prognosis. Although highly responsive to chemotherapy initially, SCLC relapses quickly and becomes refractory to treatment within a few months. The inability to destroy residual SCLC cells despite initial chemosensitivity suggests the existence of a highly effective DNA damage response network. SCLC is also characterized by high DNA replication stress (RB1 inactivation, MYC and CCNE1 activation). There is only one FDA approved treatment for patients with relapsed SCLC after first-line chemotherapy: topotecan, which inhibits religation of topoisomerase I-mediated single-strand DNA breaks leading to lethal double-strand DNA breaks. Temozolomide, an oral alkylating agent, which causes DNA damage by alkylating guanine at position O6 also has activity in relapsed SCLC, particularly for brain metastases. Preliminary evidence indicates that disruption of the immune checkpoint PD-1/PD-L1 pathway can yield responses in a subset of SCLC patients, but response rates (approximately equal to 10%) are lower than NSCLC and other tumors with comparable tumor mutational burden indicating additional immunosuppressive mechanisms at play in the SCLC tumor microenvironment. M7824 is a bifunctional fusion protein consisting of an anti-programmed death ligand 1 (PDL1) antibody and the extracellular domain of transforming growth factor beta (TGF-beta) receptor type 2, a TGF-beta trap. Safety data from the dose-escalation study in solid tumors as well as preliminary data from expansion cohorts show that M7824 has a safety profile similar to other checkpoint inhibiting compounds. Combining immunotherapy, and chemotherapy could synergistically improve the anticancer activity of immunotherapy. Combination of chemotherapy with immunotherapy have improved outcomes in NSCLC and melanoma leading to FDA approvals of such combinations. We hypothesize that increased DNA damage induced by topotecan and temozolomide will complement the anti-tumor activity of M7824, in recurrent SCLC. OBJECTIVE: - The primary objective of the trial is to determine the efficacy (using objective response rate) of M7824 plus topotecan or temozolomide in relapsed SCLC. ELIGIBILITY: Subjects with histological or cytological confirmation of SCLC. Subjects must be greater than or equal to 18 years of age and have a performance status (ECOG) less than or equal to 2. Subjects must not have received chemotherapy, or undergone major surgery within 2 weeks and radiotherapy within 24 hours prior to enrollment. Subjects must have adequate organ function and measurable disease. DESIGN: Arm A (M7824 monotherapy): Up to 10 patients may be treated with M7824 monotherapy to obtain safety and PK data, and a preliminary estimate of clinical responses to M7824 in SCLC. Patients with progressive disease on Arm A may then receive M7824 plus temozolomide as per description of treatment for Arm C. Arm B (M7824 plus topotecan) and Arm C (M7824 plus temozolomide) will be administered in 3 and 4-week cycles respectively; these arms will have a safety run-in followed by efficacy analysis. Up to 10 patients with extrapulmonary small cell cancer will be enrolled in arm C to receive the combination of M7824 and temozolomide. Optional tumor biopsies will be obtained at pre-treatment on C1D1 and C1D15 for Arm C; pre-treatment on C1D1 and C2D1 for arms A and B. Every subject of each arm of the safety run-in will be observed for at least 7 days after first dose of M7824 before the subsequent subject can be treated. Subjects who are not evaluable for DLT will be replaced and not included into evaluation ARMS: Arm A (3-week cycles): M7824 monotherapy 2400 mg every 3 weeks until disease progression or a criterion in Protocol is met. Patients with progressive disease on Arm A may then receive 1200 mg M7824 every 2 weeks plus temozolomide 200 mg/m^2/day on days 1-5 every 4 weeks. Arm B (3-week cycles): M7824 2400 mg plus topotecan 1 mg/m2 on days 1-5 every 3 weeks until disease progression or a criterion in Protocol is met. Arm C (4-week cycles): M7824 1200 mg every 2 weeks plus temozolomide 200 mg/m2/day on days 1-5 every 4 weeks until disease progression or a criterion in Protocol is met. Dose de-escalation Schedule Arm B Dose Level: M7824 - Topotecan Level 1 2400 mg every 3 weeks - 1 mg/m(2) on days 1-5 every 3 weeks Level-1 2400 mg every 3 weeks - 0.75 mg/m(2) on days 1-5 every weeks Dose de-escalation Schedule Arm C Dose Level: M7824 - Temozolomide Level 1200 mg every 2 weeks - 200 mg/m(2)/day on days 1-5 every 4 weeks Level-1 1200 mg every 2 weeks - 150 mg/m(2) day on days 1-5 every 4 weeks Read Less

Gender:

All

Ages:

Between 18 years and 99 years

Trial Updated:

05/15/2024

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer

Learn More ›

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

NCT06117774

Recruiting

The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS).

Gender:

All

Ages:

18 years and above

Trial Updated:

05/15/2024

Locations: Our Lady of the Lake Cancer Institute, Baton Rouge, Louisiana +28 locations

Our Lady of the Lake Cancer Institute, Baton Rouge, Louisiana

FirstHealth Cancer Center, Pinehurst, North Carolina

West Virginia University Health Sciences Center, Morgantown, West Virginia

Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian

Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei

Shandong Provincial Cancer Hospital, Jinan, Shandong

Shanxi Bethune Hospital, Taiyuan, Shanxi

National Hospital Organization Nagoya Medical Center, Nagoya-shi, Aichi

National Cancer Center Hospital East, Kashiwa-shi, Chiba

National Hospital Organization Shikoku Cancer Center, Matsuyama-shi, Ehime

Kurume University Hospital, Kurume-shi, Fukuoka

National Hospital Organization Hokkaido Cancer Center, Sapporo-shi, Hokkaido

Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center, Yokohama-shi, Kanagawa

Sendai Kousei Hospital, Sendai-shi, Miyagi

Niigata Cancer Center Hospital, Niigata-shi, Niigata

Okayama University Hospital, Okayama-shi, Okayama

Kansai Medical University Hospital, Hirakata-shi, Osaka

Osaka International Cancer Institute, Osaka-shi, Osaka

Kindai University Hospital, Osakasayama-shi, Osaka

Saitama Medical University International Medical Center, Hidaka-Shi, Saitama

Shizuoka Cancer Center, Sunto-gun, Shizuoka

Dokkyo Medical University Hospital, Shimotsuga-gun, Tochigi

Juntendo University Hospital, Bunkyo-ku, Tokyo

Chungbuk National University Hospital, Cheongju Chungbuk, Not set

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Not set

Taipei Veterans General Hospital, Taipei, Not set

Izmir Ekonomi Universitesi Medical Point Hastanesi, Izmir, Not set

Kocaeli Universitesi Tip Fakultesi Hastanesi, Kocaeli, Not set

Medical Park Seyhan Hastanesi, Mersin, Not set

Conditions: Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer

Learn More ›

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

NCT05619744

Recruiting

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of RO7616789. The study will have 3 parts: Dose Escalation (Parts 1 and 2) and Dose Expansion (Part 3). Participants with advanced stage small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) will be enrolled in the study.

Gender:

All

Ages:

18 years and above

Trial Updated:

05/13/2024

Locations: Georgetown Uni Medical Center; Lombardi Cancer Center, Washington, District of Columbia +15 locations

Conditions: Small Cell Lung Cancer, Neuroendocrine Carcinoma

Learn More ›

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

NCT06095505

Recruiting

PUMA-ALI-4201 is a Phase 2 study evaluating alisertib in patients with pathologically-confirmed extensive-stage small cell lung cancer (ES-SCLC) following progression on or after first-line treatment with platinum-based chemotherapy along with an anti-PDL-1 immunotherapy agent. This study is intended to evaluate the efficacy, safety, and pharmacokinetics of alisertib and to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment.

Gender:

All

Ages:

18 years and above

Trial Updated:

05/09/2024

Locations: Southern Cancer Center, Daphne, Alabama +18 locations

Conditions: Small Cell Lung Cancer

Learn More ›

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526

Recruiting

This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.

Gender:

All

Ages:

18 years and above

Trial Updated:

05/09/2024

Locations: Highlands Oncology Group, Springdale, Arkansas +36 locations

Highlands Oncology Group, Springdale, Arkansas

University of California at Davis, Davis, California

The Oncology Institute of Hope and Innovation, Downey, California

City of Hope Cancer Center, Duarte, California

University of Colorado Hospital, Aurora, Colorado

Nuvance Health, Norwalk, Connecticut

MedStar Georgetown University Hospital, Washington, District of Columbia

Florida Cancer Specialists, Atlantis, Florida

University of Florida Health Cancer Center, Gainesville, Florida

Ocala Oncology Florida Cancer Affiliates, Ocala, Florida

AdventHealth Cancer Institute, Orlando, Florida

Memorial Cancer Institute, Pembroke Pines, Florida

Emory University Winship Cancer Institute, Atlanta, Georgia

Norton Health, Lexington, Kentucky

Greater Baltimore Medical Center, Baltimore, Maryland

The Center for Cancer and Blood Disorders, Bethesda, Maryland

Dana Farber Cancer Institute, Boston, Massachusetts

Massachusetts General Hospital, Boston, Massachusetts

University of Michigan Medical Center, Ann Arbor, Michigan

Atlantic Healthcare System, Morristown, New Jersey

Memorial Sloan Kettering Cancer Center, New York, New York

University of Cincinnati Medical Center, Cincinnati, Ohio

The Ohio State University James Cancer Center, Columbus, Ohio

Zangmeister Cancer Center, Columbus, Ohio

Pennsylvania Cancer Specialists & Research Institute (Formerly Gettysburg Cancer Center), Gettysburg, Pennsylvania

Prisma Health, Greenville, South Carolina

Tennessee Oncology Chattanooga Memorial Plaza, Chattanooga, Tennessee

Tennessee Oncology - Nashville, Nashville, Tennessee

Houston Methodist Cancer Center, Houston, Texas

Oncology Consultants, Houston, Texas

University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

NEXT/Virginia Cancer Specialists, Fairfax, Virginia

University of Washington / Fred Hutchinson Cancer Center, Seattle, Washington

Newcastle Private Hospital, New Lambton Heights, New South Wales

Tasman Oncology Research, Southport, Queensland

Cancer Research SA, Adelaide, South Australia

Southern Oncology Clinical Research Unit, Bedford Park, South Australia

Conditions: Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma

Learn More ›

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

NCT04624204

Recruiting

The purpose of this study is to compare overall survival (OS) and progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR). Hypothesis (H1): Concurrent chemoradiation therapy with pembrolizumab followed by pembrolizumab plus olaparib is superior to concurrent chemoradiation therapy alone with respect to PFS per RECIST 1.1 by BICR. Hypothesis (H2): Concurrent chemoradiation therapy with pem... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

05/03/2024

Locations: Ironwood Cancer & Research Centers ( Site 0007), Chandler, Arizona +185 locations

Ironwood Cancer & Research Centers ( Site 0007), Chandler, Arizona

Loma Linda University Cancer Center ( Site 0011), Loma Linda, California

Georgetown University ( Site 0017), Washington, District of Columbia

Moffitt Cancer Center ( Site 0137), Tampa, Florida

University of Chicago Medical Center ( Site 0136), Chicago, Illinois

Fort Wayne Medical Oncology and Hematology ( Site 0034), Fort Wayne, Indiana

University of Kentucky Chandler Medical Center ( Site 0138), Lexington, Kentucky

Overton Brooks VAMC ( Site 0041), Shreveport, Louisiana

Harry & Jeanette Weinberg Cancer Institute ( Site 0045), Baltimore, Maryland

VA Ann Arbor Healthcare System ( Site 0050), Ann Arbor, Michigan

St. Vincent Healthcare Frontier Cancer Center ( Site 0056), Billings, Montana

Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0061), Omaha, Nebraska

Memorial Sloan Kettering - Basking Ridge ( Site 0133), Basking Ridge, New Jersey

John Theurer Cancer Center ( Site 0064), Hackensack, New Jersey

Memorial Sloan Kettering - Monmouth ( Site 0135), Middletown, New Jersey

Memorial Sloan Kettering - Bergen ( Site 0130), Montvale, New Jersey

Rutgers Cancer Institute of New Jersey ( Site 0123), New Brunswick, New Jersey

Memorial Sloan Kettering- Commack ( Site 0132), Commack, New York

Memorial Sloan Kettering - Westchester-Thoracic Oncology ( Site 0134), Harrison, New York

Memorial Sloan Kettering Cancer Center ( Site 0069), New York, New York

Memorial Sloan Kettering - Nassau ( Site 0131), Uniondale, New York

Fairview Hospital-Moll Cancer Center ( Site 0141), Cleveland, Ohio

Cleveland Clinic Main ( Site 0139), Cleveland, Ohio

Cleveland Clinic - Hillcrest Hospital-Hillcrest Hospital Cancer Center ( Site 0140), Mayfield Heights, Ohio

Penn State Hershey Cancer Institute ( Site 0081), Hershey, Pennsylvania

Saint Francis Cancer Center ( Site 0087), Greenville, South Carolina

The University of Tennessee Medical Center ( Site 0116), Knoxville, Tennessee

Texas Oncology - Dallas (Presbyterian)_McIntyre ( Site 0098), Dallas, Texas

Texas Oncology - Dallas (Sammons) ( Site 0093), Dallas, Texas

MD Anderson Cancer Center ( Site 0100), Houston, Texas

Millennium Research & Clinical Development ( Site 0143), Houston, Texas

Providence Regional Cancer Partnership ( Site 0106), Everett, Washington

Medical Oncology Associates, PS ( Site 0142), Spokane, Washington

Multicare Institute For Research And Innovation ( Site 0108), Tacoma, Washington

Virginia Mason Memorial- North Star Lodge Cancer Center ( Site 0112), Yakima, Washington

Campbelltown Hospital ( Site 3002), Campbelltown, New South Wales

Nepean Hospital ( Site 3001), Kingswood, New South Wales

Calvary Mater Newcastle ( Site 3000), Waratah, New South Wales

Gold Coast University Hospital ( Site 3003), Southport, Queensland

Frankston Hospital-Oncology and Haematology ( Site 3007), Frankston, Victoria

Austin Health-Austin Hospital ( Site 3006), Heidelberg, Victoria

Western Health-Sunshine Hospital ( Site 3004), St Albans, Victoria

Saint-Luc UCL ( Site 1005), Brussels, Bruxelles-Capitale, Region De

Grand Hopital de Charleroi ( Site 1003), Charleroi, Hainaut

C.I.U. Hopital Ambroise Pare ( Site 1001), Mons, Hainaut

CHU UCL Namur Site de Godinne ( Site 1004), Yvoir, Namur

UZ Leuven ( Site 1002), Leuven, Vlaams-Brabant

AZ Delta ( Site 1000), Roeselare, West-Vlaanderen

MHAT "Uni Hospital" OOD ( Site 2507), Panagyurishte, Pazardzhik

Cross Cancer Institute ( Site 0206), Edmonton, Alberta

Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0212), Hamilton, Ontario

CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0202), Montreal, Quebec

McGill University Health Centre ( Site 0210), Montréal, Quebec

CIUSSS de la Mauricie et du Centre du Quebec ( Site 0200), Trois-Rivieres, Quebec

Beijing Cancer Hospital ( Site 3127), Beijing, Beijing

Peking Union Medical College Hospital ( Site 3102), Beijing, Beijing

Cancer Hospital Chinese Academy of Medical Sciences ( Site 3104), Beijing, Beijing

Beijing Cancer hospital-Oncology Radiotherapy Department ( Site 3140), Beijing, Beijing

Chongqing Cancer Hospital ( Site 3135), Chongqing, Chongqing

Daping Hospital,Third Military Medical University ( Site 3136), Chongqing, Chongqing

Fujian Provincial Cancer Hospital ( Site 3126), Fuzhou, Fujian

The First Affiliated Hospital of Xiamen University ( Site 3121), Xiamen, Fujian

Peking University Shenzhen Hospital ( Site 3118), Shenzhen, Guangdong

Cancer Hospital Chinese Academy Of Medical Sciences. Shenzhen Center ( Site 3113), Shenzhen, Guangdong

Henan Cancer Hospital ( Site 3105), Zhengzhou, Henan

Wuhan Union Hospital ( Site 3123), Wuhan, Hubei

Tongji Medical College Huazhong University of Science and Technology ( Site 3138), Wuhan, Hubei

Hubei Cancer Hospital ( Site 3120), Wuhan, Hubei

Hunan Cancer Hospital ( Site 3133), Changsha, Hunan

Xiangya Hospital of Central South University ( Site 3137), Changsha, Hunan

Second Xiangya Hospital of Central-South University ( Site 3128), Changsha, Hunan

Jiangsu Cancer Hospital ( Site 3139), Nanjing, Jiangsu

The Second Affiliated Hospital of Nanchang University ( Site 3106), Nanchang, Jiangxi

The First Hospital of Jilin University ( Site 3132), Changchun, Jilin

Shandong Province Cancer Hospital ( Site 3100), Jinan, Shandong

Shanghai Chest Hospital ( Site 3107), Shangai, Shanghai

Shanghai Pulmonary Hospital ( Site 3101), Shanghai, Shanghai

West China Hospital of Sichuan University ( Site 3114), Chengdu, Sichuan

Tianjin Medical University Cancer Institute & Hospital ( Site 3103), Tianjin, Tianjin

Hangzhou Cancer Hospital ( Site 3129), Hanghzou, Zhejiang

The 1st Affil Hosp of College of Medicine, Zhejiang Univ ( Site 3131), Hangzhou, Zhejiang

Zhejiang Cancer Hospital.... ( Site 3108), Hangzhou, Zhejiang

SA Pohja-Eesti Regionaalhaigla ( Site 2201), Tallinn, Harjumaa

SA Tartu Ulikooli Kliinikum ( Site 2200), Tartu, Tartumaa

C.H. de Saint Quentin ( Site 1111), Saint Quentin, Aisne

CHU de Bordeaux Hop St ANDRE ( Site 1115), Bordeaux, Aquitaine

Clinique Clairval ( Site 1108), Marseille, Bouches-du-Rhone

Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 1105), Paris, Ile-de-France

CHU Grenoble -Hop Michallon ( Site 1102), Grenoble, Isere

Institut De Cancerologie De L Ouest ( Site 1110), Saint Herblain, Loire-Atlantique

Institut de Cancerologie de l Ouest Site Paul Papin ( Site 1103), Angers, Maine-et-Loire

Hopital Avicenne ( Site 1106), Bobigny, Seine-Saint-Denis

H.I.A. Sainte-Anne ( Site 1101), Toulon, Var

Henry Dunant Hospital ( Site 1205), Athens, Attiki

Sotiria Regional Chest Diseases Hospital of Athens ( Site 1200), Athens, Attiki

University General Hospital of Herakleion ( Site 1202), Heraklion, Irakleio

Anti-Cancer Hospital of Thessaloniki Theagenio ( Site 1204), Thessaloniki, Kentriki Makedonia

University General Hospital of Larisa ( Site 1201), Larissa, Thessalia

Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1306), Kecskemét, Bacs-Kiskun

Petz Aladar Megyei Oktato Korhaz ( Site 1312), Gyor, Gyor-Moson-Sopron

Reformatus Pulmonologiai Centrum ( Site 1304), Torokbalint, Pest

Orszagos Koranyi Pulmonologiai Intezet ( Site 1301), Budapest, Not set

Orszagos Onkologiai Intezet ( Site 1310), Budapest, Not set

Uzsoki Utcai Korhaz ( Site 1303), Budapest, Not set

Rambam Health Care Campus-Oncology Division ( Site 1401), Haifa, Not set

Chaim Sheba Medical Center ( Site 1400), Ramat Gan, Not set

A O U Policlinico di Modena ( Site 1503), Modena, Emilia-Romagna

Azienda Ospedaliero Universitaria Careggi ( Site 1509), Florence, Firenze

Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento-Oncology Unit ( Site 1513, Verona, Veneto

Azienda Ospedaliera Spedali Civili di Brescia ( Site 1512), Brescia, Not set

IRCCS Ospedale San Raffaele ( Site 1500), Milano, Not set

Istituto Nazionale dei Tumori ( Site 1504), Milano, Not set

Istituto Europeo di Oncologia ( Site 1501), Milano, Not set

IRCCS Istituto Oncologico Veneto ( Site 1506), Padova, Not set

Policlinico Universitario Agostino Gemelli ( Site 1505), Roma, Not set

Aichi Cancer Center Hospital ( Site 4010), Nagoya, Aichi

Kobe Minimally Invasive Cancer Center ( Site 4003), Kobe, Hyogo

Takarazuka City Hospital ( Site 4013), Takarazuka, Hyogo

Kanagawa Cancer Center ( Site 4001), Yokohama, Kanagawa

Kansai Medical University Hospital ( Site 4009), Hirakata, Osaka

Osaka Medical and Pharmaceutical University Hospital ( Site 4007), Takatsuki, Osaka

Shizuoka Cancer Center ( Site 4014), Nagaizumi, Shizuoka

National Hospital Organization Kyushu Cancer Center ( Site 4000), Fukuoka, Not set

Niigata Cancer Center Hospital ( Site 4004), Niigata, Not set

Okayama University Hospital ( Site 4012), Okayama, Not set

Osaka International Cancer Institute ( Site 4005), Osaka, Not set

National Cancer Center Hospital ( Site 4015), Tokyo, Not set

Juntendo University Hospital ( Site 4008), Tokyo, Not set

Tokyo Metropolitan Komagome Hospital ( Site 4011), Tokyo, Not set

The Cancer Institute Hospital of JFCR ( Site 4006), Tokyo, Not set

Showa University Hospital ( Site 4002), Tokyo, Not set

National Cancer Center ( Site 3306), Goyang-si, Kyonggi-do

Seoul National University Bundang Hospital ( Site 3301), Seongnam-si, Kyonggi-do

The Catholic University of Korea St. Vincent s Hospital ( Site 3303), Suwon-si, Kyonggi-do

Inje University Haeundae Paik Hospital ( Site 3307), Busan, Pusan-Kwangyokshi

Asan Medical Center ( Site 3308), Songpagu, Seoul

Keimyung University Dongsan Hospital ( Site 3302), Daegu, Taegu-Kwangyokshi

Severance Hospital Yonsei University Health System ( Site 3304), Seoul, Not set

Samsung Medical Center ( Site 3300), Seoul, Not set

Nacionalinis Vezio Institutas ( Site 2300), Vilnius, Vilniaus Miestas

LSMUL Kauno Klinikos ( Site 2301), Kaunas, Not set

Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0401), Guadalajara, Jalisco

Hospital Universitario "Dr. Jose Eleuterio Gonzalez" ( Site 0404), Monterrey, Nuevo Leon

Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE ( Site 1705), Lisboa, Not set

Centro Hospitalar Lisboa Norte E.P.E. - Hospital Pulido Valente ( Site 1704), Lisboa, Not set

Instituto Portugues de Oncologia Do Porto Francisco Gentil E.P.E. ( Site 1701), Porto, Not set

Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2803), Cluj-Napoca, Cluj

Amethyst Radiotherapy Center-Oncologie Medicala ( Site 2805), Florești, Cluj

Spitalul Municipal Ploiesti ( Site 2801), Ploiesti, Prahova

Cabinet Medical Oncomed ( Site 2802), Timisoara, Timis

S.C.Focus Lab Plus S.R.L ( Site 2804), Bucuresti, Not set

Moscow Regional Oncological Dispensary-Oncology (thoracic surgery) Department №1 ( Site 1815), Balashikha, Moskovskaya Oblast

Main Military Clinical Hospital n.a. N.N.Burdenko ( Site 1812), Moscow, Moskva

MROI n.a. P.A. Herzen - branch of FSBI NMICR of MoH of Russia ( Site 1800), Moscow, Moskva

Nizhniy Novgorod Region Oncology Dispensary ( Site 1811), Nizhny Novgorod, Nizhegorodskaya Oblast

Omsk Clinical Oncology Dispensary ( Site 1806), Omsk, Omskaya Oblast

Sverdlovsk Regional Oncology Hospital ( Site 1807), Ekaterinburg, Sverdlovskaya Oblast

Republican Clinical Oncology Dispensary-Chemotherapy #1 ( Site 1814), Kazan, Tatarstan, Respublika

Institute for Oncology and Radiology of Serbia ( Site 2995), Belgrade, Beograd

Institut za plucne bolesti Vojvodine Sremska Kamenica ( Site 2991), Sremska Kamenica, Sremski Okrug

Steve Biko Academic Hospital ( Site 5000), Pretoria, Gauteng

Groote Schuur Hospital ( Site 5002), Cape Town, Western Cape

Hospital Universitario Central de Asturias ( Site 1900), Oviedo, Asturias

Hospital Duran i Reynals ( Site 1903), Hospitalet de Llobregat, Barcelona

Hospital Universitari Vall d Hebron ( Site 1904), Barcelona, Not set

Hospital Universitario 12 de Octubre ( Site 1902), Madrid, Not set

Hospital Regional Universitario de Malaga ( Site 1905), Malaga, Not set

Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 1907), Sevilla, Not set

Ankara Bilkent Sehir Hastanesi ( Site 2007), Ankara, Not set

Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 2009), Istanbul, Not set

Medipol Universite Hastanesi ( Site 2005), Istanbul, Not set

Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 2003), Istanbul, Not set

Ege Universitesi Tip Fakultesi Hastanesi ( Site 2001), Izmir, Not set

Medical center Medikal Plaza of Ecodnipro LLC ( Site 2107), Dnipro, Dnipropetrovska Oblast

Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 2110), Kharkiv, Kharkivska Oblast

Medical Center of Yuriy Spizhenko LLC.-Clinical Trial ( Site 2104), Kapitanivka Village, Kyivska Oblast

Clinic of National Cancer Institute ( Site 2101), Kyiv, Kyivska Oblast

Medical Center Verum ( Site 2106), Kyiv, Kyivska Oblast

LISOD. Hospital ( Site 2111), Pliuty, Kyiv

Kyiv City Clinical Oncology Center ( Site 2100), Kyiv, Not set

Royal Infirmary Aberdeen ( Site 2403), Aberdeen, Aberdeen City

Ninewells Hospital and Medical School ( Site 2401), Dundee, Dundee City

Taunton and Somerset Hospital ( Site 2404), Taunton, England

Barts Health NHS Trust ( Site 2409), London, London, City Of

Guy s & St Thomas NHS Foundation Trust ( Site 2408), London, London, City Of

The Christie NHS Foundation Trust ( Site 2405), Manchester, Not set

Conditions: Small Cell Lung Cancer

Learn More ›

Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

NCT05983432

Recruiting

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

Gender:

All

Ages:

18 years and above

Trial Updated:

05/02/2024

Locations: SystImmune Recruiting Site, Orange, California +9 locations

Conditions: Non Small Cell Lung Cancer, NSCLC, Lung Cancer, Breast Cancer, Esophageal Cancer, SCLC, Small Cell Lung Cancer, NPC, Nasopharyngeal Cancer

Learn More ›

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT06257264

Recruiting

This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors. The study will also identify a recommended dose for expansion (RDFE) in subsequent disease directed studies. The study will be conducted in 2 parts: Part 1 (dose escalation and safety e... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/23/2024

Locations: Washington University School of Medicine, Saint Louis, Missouri +4 locations

Conditions: Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer

Learn More ›

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

NCT02769962

Recruiting

Background: EP0057 consists of a sugar molecule cyclodextrin linked to a chemotherapy drug called camptothecin. The combined molecule or "nanoparticle drug conjugate" travels through the blood. Once inside cancer cells, the chemotherapy drug is released from the molecule. Olaparib is a drug that may stop cancer cells from repairing the DNA damage caused by chemotherapy. Researchers want to see how safe it is to give EP0057 and olaparib together and to see how well the combination treats a specif... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/03/2024

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Urothelial Carcinoma, Urothelial Cancer, Lung Neoplasms, Small Cell Lung Cancer, Prostate Cancer

Learn More ›

Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study

NCT05257551

Recruiting

The study is a non-interventional evaluation of participants with SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA biomarker profiling in addition to their standard of care therapy and disease surveillance.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/02/2024

Locations: Cancer and Blood Specialty Clinic, Los Alamitos, California +9 locations

Conditions: Small Cell Lung Cancer

Learn More ›

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

NCT05271292

Recruiting

This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.

Gender:

All

Ages:

18 years and above

Trial Updated:

03/18/2024

Locations: California Cancer Associates-Encintas, Encinitas, California +10 locations

Conditions: Advanced Solid Malignant Tumor, Small Cell Lung Cancer

Learn More ›

1 - 12 of 22